Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. - Wikidata - wikimedia - TriplyDB

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

http://www.wikidata.org/entity/Q34049228

about

BRCAness: finding the Achilles heel in ovarian cancer Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer Cytotoxic and targeted therapy for hereditary cancers Cancer predisposition genes: molecular mechanisms and clinical impact on personalized cancer care: examples of Lynch and HBOC syndromes Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer The role of PARP in DNA repair and its therapeutic exploitation PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies The `dnet’ approach promotes emerging research on cancer patient survival Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment Integrating cancer genomic data into electronic health records Patient-derived tumour xenografts for breast cancer drug discovery PALB2: the hub of a network of tumor suppressors involved in DNA damage responses Peptide library approach to uncover phosphomimetic inhibitors of the BRCA1 C-terminal domain RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination PARP inhibitor treatment in ovarian and breast cancer The relative efficiency of homology-directed repair has distinct effects on proper anaphase chromosome separation.curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome Más-o-menos: a simple sign averaging method for discrimination in genomic data analysis.Bayesian clinical classification from high-dimensional data: Signatures versus variability.Pathway-Informed Classification System (PICS) for Cancer Analysis Using Gene Expression Data.Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer.Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells.Metabolic profiling and novel plasma biomarkers for predicting survival in epithelial ovarian cancer.Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy Molecular genetics complexity impeding research progress in breast and ovarian cancers.Investigational agents in development for the treatment of ovarian cancer Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.Neuronal transcription factor Brn-3a(l) is over expressed in high-grade ovarian carcinomas and tumor cells from ascites of patients with advanced-stage ovarian cancer Prognostic biomarkers in ovarian cancer.BRCAness profile of sporadic ovarian cancer predicts disease recurrence.PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.

P2860

Q24630872-FD088763-F1F2-4CEF-AFF5-3050B7287EB2 Q24632628-BF77B0BA-4D05-4F09-921D-1AEDEB231E7F Q26739366-FBE64C04-E976-49A1-91BA-158DE8C2932D Q26776258-4491885E-2AC3-4B91-8D25-DFD66E7824C2 Q26783551-FCAF7D35-4C7E-4F07-9436-22C8FEDB2647 Q26852274-E0BAB198-44AF-4F12-86F7-47BDC0A1C49D Q26859166-F5077F18-9D83-48D8-8166-E53082D07B92 Q27002399-1FFE8B81-2FE7-41F8-A3D4-3BF7AC23E07B Q27027503-91437AD6-6063-4268-8B2B-1C5F146BAC0B Q27499832-5737928B-E4ED-4D3D-B00A-E6723AF5DE8E Q28071541-634C772E-D06E-49C6-BB30-4929AAA0ED4E Q28075761-5A695E4E-0FDB-437E-AF76-483F99EE8A5F Q28077310-8B18CCC1-603C-47F4-8606-149EFF041744 Q28080046-98FB3411-5C61-4112-BE04-B06613B59B38 Q28243398-54FB5B8E-5B9A-4743-9D4B-F47D3D57FFDD Q28256541-8B731550-2E98-4EBE-8D6C-2975BC666DEA Q28274789-7F5F2007-A335-41E4-899D-ED87D92F9668 Q28741688-DF6643E1-E1DF-4B75-95BB-A5F74F07C06C Q30503322-F658F64A-D69C-4263-B493-E5511285F792 Q30611147-8A2D344B-117F-42AA-A444-85680655E8B3 Q30838620-40301E36-922C-4420-9569-0332C10B83E8 Q31059415-368CBC62-58E9-44A6-9E94-B8A11FC779F0 Q31119292-590FFC56-628C-4E4D-BC5F-F8D8159B743A Q33415400-FBB3D979-3E2E-4976-9FEA-0028713678D2 Q33415790-860E1B96-ED46-48D6-8DED-BC703FB9E5D6 Q33565650-FD824E15-0EB1-47F5-A214-BCFD97790687 Q33731278-1FE39080-595B-49BA-A7FE-6B65F4BAEFB9 Q33739161-B1886453-EE9D-4DC4-9DAE-DFC71E00F6B9 Q33750060-74AC5F96-DCB4-448E-A252-582CFAB9DAE4 Q33757073-3E256D35-2656-48F4-BBF5-9CAFDCE6C6E8 Q33762042-C28D1102-D621-4FC6-B1BB-C17D3E2DB606 Q33798999-34925035-4156-46B9-AD57-7966B3C31B1C Q33827045-B294DAC8-FC4A-4CAA-915C-C5694604AAA7 Q33858073-DF611438-3CC1-4674-8D61-6C83158C1037 Q33920800-57C28EB7-E726-4641-83EC-08CA2B73D2BA Q33974923-9D2EB86D-4054-4E7C-8A8B-81D7656C63C8 Q34060699-CAF3B109-0A7D-428C-A522-84DC3AC49025 Q34086636-3DB308FB-1159-4859-9802-51B586D7AC10 Q34130956-D2A1205B-19A3-4BC6-8D83-5274A5494F1E Q34215904-7D4167D2-CD4F-40A6-BF17-4C4061B3260E

P2860

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

http://www.wikidata.org/entity/Q34049228

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Gene expression profile of BRC ...... ith epithelial ovarian cancer.

@ast

Gene expression profile of BRC ...... ith epithelial ovarian cancer.

@en

Gene expression profile of BRC ...... ith epithelial ovarian cancer.

@nl

type

label

Gene expression profile of BRC ...... ith epithelial ovarian cancer.

@ast

Gene expression profile of BRC ...... ith epithelial ovarian cancer.

@en

Gene expression profile of BRC ...... ith epithelial ovarian cancer.

@nl

prefLabel

Gene expression profile of BRC ...... ith epithelial ovarian cancer.

@ast

Gene expression profile of BRC ...... ith epithelial ovarian cancer.

@en

Gene expression profile of BRC ...... ith epithelial ovarian cancer.

@nl

P1433

Q34049228-6855BE71-62C6-4755-ACCA-98E55DF2E65E

P1476

Q34049228-5E623030-1030-4ED4-8E0F-38E9AB5252E9

P2093

Q34049228-0BC6BABF-7E11-49BC-A2CA-FEE3E1B4B419

Q34049228-17C7C7C1-DD31-4B26-85F7-772C3CEF3F50

Q34049228-8EFEDE1B-ECC4-4FB1-A65B-77220F1D3BBA

Q34049228-A82A86CD-C283-4C6F-AA35-A703F6499F89

Q34049228-BD6BAB95-53ED-46FD-8488-B53B7C803766

Q34049228-E3AF3C17-78F7-4426-8D0F-E43B4B261F83

Q34049228-F292BEFC-862A-4094-8828-56365028E1D3

P2860

Q34049228-008DF98D-8E89-4A6F-8AA4-B533734998F3

Q34049228-0AA107D5-997C-4B0E-97A3-24A5FDBF04FD

Q34049228-12820E87-3F50-4A99-AAB3-A6F36939CD88

Q34049228-21264604-17D6-415A-B57E-DB399C3C53E3

Q34049228-29D845C7-A29D-4355-BC40-2D9A6DA18C27

Q34049228-2D823276-E4CF-4D88-923F-66ADF8B6B7CE

Q34049228-31F059E1-BD6A-4157-A0DB-360F61F34337

Q34049228-344E2C72-8B83-4360-AF1C-8EFCA5ECDF87

Q34049228-3810A35B-FE25-4B30-AD5E-F87B2D312CD5

Q34049228-3C07D503-01A5-427C-952F-D71EC212DEE8

P304

Q34049228-CAD84097-6AE4-452E-8124-EFDDB3ED5393

P31

Q34049228-6DF08CA5-920D-4AD0-8FA9-E0B830AA6053

P356

Q34049228-C7CC18BA-5AD8-4996-B884-3F5B3DA6763C

P407

Q34049228-EB87D034-7EDD-4807-BBCA-02E98834E395

P433

Q34049228-24344747-271C-4E15-AE26-94E31890F8EF

P478

Q34049228-728E4642-DD59-41FA-B522-54630890F2D8

P50

Q34049228-8E0467AC-7634-4104-8BBA-BF0EDC0085E2

P577

Q34049228-4BEB624D-5045-4BD0-B23F-8748ACB95A75

P698

Q34049228-D314B36A-15A5-42E1-BF58-79652B0C8D28

P921

Q34049228-40B5913B-5008-4A40-AC06-D535174EF473

Q34049228-94CCCCF1-1BAD-4469-B558-F3A481A6A4AF

Q34049228-9F4A6ADE-2808-44A9-BC81-D2A2C0C43445

P932

Q34049228-909B95CB-D5B2-4B13-BBA3-D7950D52FDD3

P356

JCO.2009.27.5719

P1433

Journal of Clinical Oncology

P1476

Gene expression profile of BRC ...... with epithelial ovarian cancer

@en

P2093

Beth Y Karlan

http://www.w3.org/2001/XMLSchema#string

Dimitrios Spentzos

http://www.w3.org/2001/XMLSchema#string

Douglas A Levine

http://www.w3.org/2001/XMLSchema#string

Elena Fountzilas

http://www.w3.org/2001/XMLSchema#string

Nancy Francoeur

http://www.w3.org/2001/XMLSchema#string

Panagiotis A Konstantinopoulos

http://www.w3.org/2001/XMLSchema#string

Stephen A Cannistra

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Abasic site recognition by two apurinic/apyrimidinic endonuclease families in DNA base excision repair: the 3' ends justify the means

EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer

Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors

The Fanconi anaemia/BRCA pathway

Resistance to therapy caused by intragenic deletion in BRCA2

Hallmarks of 'BRCAness' in sporadic cancers

Optimality driven nearest centroid classification from genomic data.

Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer

P304

3555-3561

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.27.5719

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Toshiyasu Taniguchi

P577

2010-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20547991

http://www.w3.org/2001/XMLSchema#string

P921

P932

2917311

http://www.w3.org/2001/XMLSchema#string